News

A recent case report describes a patient with relapsed/refractory aggressive SM treated with enasidenib after other treatments failed.

Lipid-lowering medications (LLMs) may increase the risk of severe anaphylactic reactions, which would greatly affect patients with SM.

In a recent study, researchers investigated the effectiveness of adrenaline autoinjectors for the prevention of fatal outcomes in anaphylaxis.

A recent case report described a patient who underwent a bone marrow transplant for acute myeloid leukemia and was later diagnosed with SM.

Indolent systemic mastocytosis (ISM) appears to significantly affect activities of daily living in over 50% of patients.

A new study detailed cellular and other changes resulting from avapritinib therapy for systemic mastocytosis.

The cellular marker CD30 appears to play a key role in cutaneous mastocytosis, which differs from systemic mastocytosis, a new study says.

Patients with mast cell activation syndrome (MCAS) could require annual controls to detect potential progression to systemic mastocytosis.

A new case study reported promising results for a man who started experimental therapy for SM symptoms after other treatment failed.

Increased awareness and diagnosis of SM could increase the growth of the SM pharmaceutical market by 2034.